Compare PHVS & PRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHVS | PRDO |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2020 | 1997 |
| Metric | PHVS | PRDO |
|---|---|---|
| Price | $31.56 | $29.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | $41.82 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.0M | 482.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.75% |
| EPS Growth | N/A | ★ 10.50 |
| EPS | N/A | ★ 1.60 |
| Revenue | N/A | ★ $581,296,000.00 |
| Revenue This Year | N/A | $4.28 |
| Revenue Next Year | N/A | $2.89 |
| P/E Ratio | ★ N/A | $18.76 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.65 | $26.66 |
| 52 Week High | $43.25 | $38.50 |
| Indicator | PHVS | PRDO |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 29.51 |
| Support Level | $25.17 | $29.22 |
| Resistance Level | $36.80 | $34.98 |
| Average True Range (ATR) | 1.83 | 1.05 |
| MACD | -0.73 | -0.33 |
| Stochastic Oscillator | 3.52 | 11.92 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.